Answers are grounded in this paper and cite their sources.
Background The life sciences industry increasingly acknowledges that meaningful patient engagement (PE) is no longer optional [1, 2]. It is a strategic imperative for ensuring the clinical relevance, regulatory success, and long-term commercial viability of new interventions; and it requires a specialized, rigorous skillset. The increasing democratization of information and integration of Artificial intelligence (AI) further demonstrates the importance of the patient voice in shaping care pathways, advocating for access, and addressing what matters most to patients [3]. Over the past 5 years patient perspectives have been increasingly integrated within regulatory processes around the world [3, 4]. The current lack of a standardized competency framework, however, has resulted in fragmented and inconsistent practices across the sector. Methods Following PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines, a systematic scoping review was conducted via the Dialog (ProQuest) platform across MEDLINE, Embase, and BIOSIS (2005 to 2025). The search combined MeSH and Emtree thesauri with title/abstract proximity operators. Dual independent screening identified 23 eligible frameworks. Stakeholder consultation following the Levac framework engaged a 12-member patient council and an international working group to iteratively refine and validate the competency architecture. Results The 4E Competency Model is organized into four distinct tiers: Essential , Enhanced , Expert , and Enable . This layered approach allows organizations to map specific skills—ranging from foundational communication and ethical compliance to strategic leadership and organizational governance—to the appropriate professional roles. The model also accounts for patient engagement within the broader life sciences ecosystem by analyzing key contextual factors that influence the successful implementation of these skills. These include regulatory boundaries, organizational culture, resource availability, and timing within the drug lifecycle. Conclusions By adopting this structured, evidence-based model, the life sciences sectors can transition from superficial, tokenistic involvement toward more equitable, high-impact patient partnerships that enhance both clinical outcomes and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Costea et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: